Proactive Investors - Run By Investors For Investors

“It is important to keep adding products,” says Clinigen’s Chilton

Shaun Chilton, deputy chief executive of ambitious specialty pharma group Clinigen (LON:CLIN), says the company is making strides towards its goal of owning ten products by 2020.

The firm, which also released its interim results this morning, announced it has bulked up its medicine cabinet with the acquisition of a product called Totect, which is used in cancer care.

The product is used to treat toxic effects of anticancer treatment - Anthracycline - and is licensed in the US, where “interestingly, at the moment there is no treatment, for this particular indication,” Chilton says.

Totect is Clinigen’s sixth product since its inception in 2010, and Chilton says “we are maintaining that strike rate of a product a year.”

Meet Gold Road Resources Ltd, Cellmid Ltd, Gold Road Resources Ltd, Altech Chemicals Ltd and Silver City Minerals Ltd at our event, Sydney, 03 October 2017. Register here »
View full CLIN profile View Profile

Clinigen Group PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use